Zoetis (NYSE:ZTS)‘s stock had its “buy” rating reaffirmed by research analysts at Jefferies Group in a report released on Tuesday. They currently have a $89.00 target price on the stock. Jefferies Group’s target price indicates a potential upside of 17.82% from the company’s current price.
A number of other analysts have also recently issued reports on the company. Morgan Stanley raised Zoetis from an “equal weight” rating to an “overweight” rating and set a $80.00 price objective on the stock in a report on Wednesday, November 29th. Zacks Investment Research cut Zoetis from a “buy” rating to a “hold” rating in a report on Wednesday, November 1st. BidaskClub raised Zoetis from a “sell” rating to a “hold” rating in a report on Friday, October 13th. Cantor Fitzgerald set a $80.00 price target on Zoetis and gave the company a “buy” rating in a report on Tuesday, December 12th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and issued a $65.00 price target on shares of Zoetis in a report on Tuesday, October 24th. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and fourteen have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $73.00.
Shares of Zoetis (NYSE ZTS) traded up $0.14 on Tuesday, reaching $75.54. The company had a trading volume of 2,600,000 shares, compared to its average volume of 1,960,000. The stock has a market cap of $36,810.00, a PE ratio of 39.76, a price-to-earnings-growth ratio of 1.90 and a beta of 1.06. The company has a debt-to-equity ratio of 2.45, a current ratio of 2.80 and a quick ratio of 1.95. Zoetis has a twelve month low of $52.00 and a twelve month high of $76.40.
Several hedge funds and other institutional investors have recently made changes to their positions in ZTS. Janus Henderson Group PLC raised its holdings in shares of Zoetis by 7,717.4% during the 2nd quarter. Janus Henderson Group PLC now owns 5,809,086 shares of the company’s stock valued at $362,372,000 after buying an additional 5,734,776 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Zoetis by 2.8% during the 2nd quarter. Vanguard Group Inc. now owns 33,654,686 shares of the company’s stock valued at $2,099,379,000 after buying an additional 910,265 shares in the last quarter. Parametric Portfolio Associates LLC raised its holdings in shares of Zoetis by 68.1% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 1,683,496 shares of the company’s stock valued at $105,016,000 after buying an additional 681,877 shares in the last quarter. Renaissance Technologies LLC raised its holdings in shares of Zoetis by 51.2% during the 2nd quarter. Renaissance Technologies LLC now owns 1,711,100 shares of the company’s stock valued at $106,738,000 after buying an additional 579,400 shares in the last quarter. Finally, Milestone Resources Group Ltd purchased a new position in shares of Zoetis during the 4th quarter valued at about $40,294,000. 93.14% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY WARNING: “Zoetis’ (ZTS) Buy Rating Reiterated at Jefferies Group” was first posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The correct version of this news story can be viewed at https://www.com-unik.info/2018/01/16/zoetis-zts-buy-rating-reiterated-at-jefferies-group.html.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.